Log in to your Inderes Free account to see all free content on this page.

Iconovo

1.14 SEK

+3.64 %

Less than 1K followers

ICO

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+3.64 %

-3.39 %

0.00 %

-28.97 %

-44.12 %

-71.39 %

-97.17 %

-97.62 %

-96.50 %

Iconovo operates in the medical technology sector. The company develops inhalers for medical use. The company's products are used in the treatment of asthma and coal, where the inhalers consist of powder-based medicine. The products are licensed and sold under various brands. In addition to product development, there is expertise in pharmaceutical formulation. The company was founded in 2013 and has its headquarters in Lund.

Market cap

109.64M SEK

Turnover

80.73K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

24.4.

2026

Interim report Q1'26

28.5.

2026

General meeting '26

20.8.

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Press releaseyesterday

DNB Carnegie Access: Iconovo: Still needs proof – Q4 review

Press release2/13/2026, 1:45 PM

DNB Carnegie Access: Iconovo - Q4 2025 - Intervju

Regulatory press release2/13/2026, 7:30 AM

The subscription period in Iconovo's rights issue begins today

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/12/2026, 1:30 PM

Iconovo publishes information document regarding rights issue of shares

Regulatory press release2/12/2026, 7:30 AM

Year-end report 1 January - 31 December 2025

Press release1/15/2026, 9:15 AM

Iconovo has initiated a new feasibility study for ICOone® Nasal in collaboration with multinational company

Press release1/13/2026, 12:40 PM

EPO declares intention to approve ICOpre® patent application

Regulatory press release12/22/2025, 9:00 AM

Nomination Committee appointed at Iconovo AB

Regulatory press release12/16/2025, 11:45 AM

Iconovo announces that the terms and conditions for allotment of shares in directed issue are met

Press release11/26/2025, 11:47 AM

DNB Carnegie Access: Iconovo: Raises capital

Regulatory press release11/25/2025, 8:05 PM

Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million, which is covered to 100% by subscription undertakings and guarantee commitments

Press release10/31/2025, 10:21 AM

DNB Carnegie Access: Iconovo: New interim CEO appointed

Regulatory press release10/31/2025, 8:35 AM

Iconovo appoints new CEO

Press release10/27/2025, 1:13 PM

Redeye: Iconovo (Q3 Review) - An uneventful quarter with solid cost-cutting

Press release10/27/2025, 8:00 AM

DNB Carnegie Access: Iconovo - Rapportintervju Q3(25)

Press release10/24/2025, 4:16 PM

DNB Carnegie Access: Iconovo: Costs down, focus sharpened – Q3 review

Regulatory press release10/24/2025, 6:30 AM

QUARTERLY REPORT Q3 2025

Press release10/14/2025, 2:26 PM

DNB Carnegie Access: Iconovo: Financial targets withdrawn

Regulatory press release10/14/2025, 1:37 PM

Iconovo reworks its strategic goals

Regulatory press release8/13/2025, 2:00 PM

Iconovo AB changes Certified Adviser to Tapper Partners AB

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.